Recent Updates
Recently added Catalysts
URGN Neutral Sentiment

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Tuesday, July 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: UroGen Pharma has announced that it will report its financial results for the second quarter of 2025 on August 7th, prior to market opening. Following this announcement, a live audio webcast and conference call will take place at 10:00 AM ET. This event will provide investors with insights into the company's financial performance and strategic direction in oncology.
Price reaction · baseline $18.9 (2025-07-28 close) · hit after-hours · clean, no other URGN news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • UroGen Pharma is set to report its financial results.
  • The webcast provides an opportunity for investors to engage.
  • The company's focus on treating urothelial and specialty cancers reflects its commitment to innovation.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+188%
120-day peak, hindsight
Typical move
18.4%
average across 4 past catalysts
Cash runway
~9 mo
Medium dilution risk
Lead asset
UGN-104
Phase 3 · Upper Urinary Tract Urothelial Carcinoma

Full Press Release Details

Conference Call and Webcast Scheduled for Thursday, August 7th, 2025, at 10:00 AM ET
PRINCETON, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2025 financial results on Thursday, August 7th, 2025, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.

Frequently Asked Questions

When will UroGen Pharma report its financial results?

UroGen Pharma will report its financial results on August 7th, 2025.

What time is the conference call scheduled for?

The conference call is set for 10:00 AM Eastern Time.

Where can I access the live webcast?

The live webcast can be accessed on UroGen’s Investor Relations website.

How long will the replay of the webcast be available?

The replay will be available for approximately 30 days.

Who can I contact for investor relations?

You can contact Vincent Perrone at 609-460-3588 ext. 1093.

ShareAdd on Google
Tags: URGN Viatris Investor Conferences Healthcare UroGen Pharma financial results biotech cancer treatment
Last updated: Jul 29, 2025

Biotech snapshot

Cash runway
$109M liquidity · $11M/mo burn
~9 mo
Medium dilution risk
Lead asset
UGN-104Phase 3
Upper Urinary Tract Urothelial Carcinoma →

Catalyst track record

+188%
best trade around URGN's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for URGN.

See every catalyst's timing & PoA →